Safety of thrombolytic therapy in normally menstruating women with acute myocardial infarction

Lanter, Patricia; Jennings, C; Roberts, Charlotte; Jesse, Robert L.

doi:10.1016/0002-9149(94)90096-5

Cited by 7 publications

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is little literature regarding the safety of thrombolysis during menstruation, and those cases reported are confined to cardiac and peripheral vascular disease, in which case most patients have received thrombolytics in conjunction with anticoagulants. [1][2][3][4][5][6][7][8][9] Of the 25 cases reported to date, only 2 have required transfusion, and no serious sequelae have occurred.…”

mentioning

confidence: 99%

Safety of Tissue Plasminogen Activator for Acute Stroke in Menstruating Women

Wein

Hickenbottom

Morgenstern

et al. 2002

Stroke

View full text Add to dashboard Cite

Background— Menses is a theoretical contraindication to intravenous tissue plasminogen activator (tPA) treatment. We sought to establish the safety of intravenous tPA in the treatment of acute ischemic stroke in women who are actively menstruating. Summary of Report— We provide a case report and review of the National Institute of Neurological Disorders and Stroke (NINDS) database for women coded as actively menstruating. Nine subjects were coded as actively menstruating in the NINDS trial (4 placebo and 5 in the treatment). One subject in the treatment group who had a 1-year history of dysfunctional uterine bleeding required emergent uterine artery ligation. We also report a case of a woman requiring transfusion after intravenous tPA administration for acute ischemic stroke. Conclusions— Intravenous tPA may be administered relatively safely in women who are menstruating and should be used with caution in women with a history of dysfunctional uterine bleeding. Potential patients should be advised that they might require transfusion for increased menstrual flow.

show abstract